Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 3, 2009, Pages 247-258

  Muller, P Y ^a   Brennan, F R ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; METHOTREXATE; MONOCLONAL ANTIBODY; TGN 1412; TRASTUZUMAB;

ANAPHYLAXIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B CELL LEUKEMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTOXICITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; IMMUNOLOGIC FACTORS; PRACTICE GUIDELINES AS TOPIC;

EID: 60349087476     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.273     Document Type: Review

References (50)

1. Keilholz, U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J. Immunother. 31, 431-439 (2008).
2. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007).
3. Yi, H., Zhang, J. & Zhao, Y. The effects of antibody treatment on regulatory CD4(+)CD25(+) T cells. Transpl. Immunol. 19, 37-44 (2008).
4. Tabrizi, M.A. & Roskos, L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12, 540-547 (2007).
5. Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028 (2006).
6. Yang, J.C. et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30, 825-830 (2007).
7. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. 〈http://www.ich.org/LOB/media/MEDIA503.pdf〉 (1997).
8. Clarke, J. et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul. Toxicol. Pharmacol. 40, 219-226 (2004).
9. Treacy, G. Using an analogous monoclonal antibody to evaluate the reproductive and chronic toxicity potential for a humanized anti-TNFalpha monoclonal antibody. Hum. Exp. Toxicol. 19, 226-228 (2000).
10. Haley, P. et al. STP position paper: best practice guideline for the routine pathology evaluation of the immune system. Toxicol. Pathol. 33, 404-407; discussion 408 (2005).
11. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. S8: Immunotoxicity Studies for Human Pharmaceuticals. 〈http://www.ich.org/LOB/media/MEDIA1706.pdf〉 (2005).
12. US Food and Drug Administration. Center for Biologics Evaluation and Research. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. 〈http://www.fda.gov/cber/gdlns/ptc-mab. pdf〉 (1997).
13. European Union. Production and Quality Control of Monoclonal Antibodies. Directive 75/318/EEC as amended. 〈http://www.emea.europa.eu/pdfs/human/bwp/ 3ab4aen.pdf〉 (1994).
14. Vargas, H.M. et al. Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics. J. Pharmacol. Toxicol. Methods 58, 72-76 (2008).
15. Schneider, C.K., Kalinke, U. & Lower, J. TGN1412 - a regulator's perspective. Nat. Biotechnol. 24, 493-496 (2006).
16. US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. 〈http://www.fda.gov/cder/Guidance/5541fnl.pdf〉 (2005).
17. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products. 〈http://www.emea. europa.eu/pdfs/human/swp/2836707enfin.pdf〉 (2007).
18. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. S9: Nonclinical Evaluation for Anticancer Pharmaceuticals (draft, step 2). 〈http://www.ich.org/LOB/media/MEDIA1706.pdf〉 (2008).
19. Nguyen, D.H., Hurtado-Ziola, N., Gagneux, P. & Varki, A. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103, 7765-7770 (2006).
20. Crocker, P.R. Siglecs in innate immunity. Curr. Opin. Pharmacol. 5, 431-437 (2005).
21. Rogers, K.A., Scinicariello, F. & Attanasio, R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol. 177, 3848-3856 (2006).
22. Jefferis, R. Antibody therapeutics: isotype and glycoform selection. Expert Opin. Biol. Ther. 7, 1401-1413 (2007).
23. Henry, S.P. et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int. Immunopharmacol. 2, 1657-1666 (2002).
24. Xu, H. et al. Studies of monkey complement: measurement of cynomolgus monkey CH50, ACH50, C4, C2 and C3. Xenotransplantation 15, 14-19 (2008).
25. Idusogie, E.E. et al. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164, 4178-4184 (2000).
26. Kang, S.P. & Saif, M.W. Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer - identification, prevention, and management. J. Support Oncol. 5, 451-457 (2007).
27. Gribble, E.J., Sivakumar, P.V., Ponce, R.A. & Hughes, S.D. Toxicity as a result of immunostimulation by biologics. Expert Opin. Drug Metab. Toxicol. 3, 209-234 (2007).
28. Expert Scientific Group. Expert Scientific Group on Phase One Clinical Trials Final Report (HMSO, London, 2006).
29. Mignot, A. High-risk molecules or insufficient scientific data? Clin. Pharmacol. Ther. 83, 365-367 (2008).
30. Mourad, G.J. et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation 65, 632-641 (1998).
31. Wise, M.P., Gallimore, A. & Godkin, A. T-cell costimulation. N. Engl. J. Med. 355, 2594-2595; author reply 2595 (2006).
32. McKeage, K. & Perry, C.M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 62, 209-243 (2002).
33. Roopenian, D.C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
34. Tabrizi, M.A., Tseng, C.M. & Roskos, L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11, 81-88 (2006).
35. Lowe, P.J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R. & Howard, D. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 37, 1331-1354 (2007).
36. Waibler, Z. et al. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS ONE 3, e1708 (2008).
37. TeGenero. Investigator's Brochure. TGN1412 Humanized Agonistic Anti-CD28 Monoclonal Antibody, edition 1.1. 〈http://www.circare.org/foia5/ tgn1412investigatorbrochure.pdf〉 (2005).
38. Stebbings, R. et al. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 179, 3325-3331 (2007).
39. Schraven, B. & Kalinke, U. CD28 superagonists: what makes the difference in humans? Immunity 28, 591-595 (2008).
40. Robinson, W.T. Innovative early development regulatory approaches: expIND, expCTA, microdosing. Clin. Pharmacol. Ther. 83, 358-360 (2008).
41. Federal Agency for Medicines and Health Products. Guidance to the Conduct of Exploratory Trials in Belgium. 〈http://www.ahppi.org.uk/CMS/STORE/ Guidance&PositionPaper/Guidance-exploratorytrials-files/ATTACHMENTS/ EXPLORATORY-GUIDELINE.doc〉 (2007).
42. US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry, Investigators, and Reviewers: Exploratory IND studies. 〈http://www.fda.gov/cder/guidance/7086fnl.pdf〉 (2006).
43. European Medicines Agency. Committee for Medicinal Products for Human Use. Position Paper on Non-Clinical Safety Studies to Support Clinical Trials with a Single Microdose. 〈http://www.emea.europa.eu/pdfs/human/swp/ 259902en.pdf〉 (2004).
44. Johansson, A. et al. Idiotypic-anti-idiotypic complexes and their in vivo metabolism. Cancer 94 (4 suppl.),1306-1313 (2002).
45. Shankar, G., Pendley, C. & Stein, K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007).
46. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins. 〈http://www.emea.europa.eu/pdfs/human/biosimilar/1432706enfin. pdf〉 (2007).
47. Mire-Sluis, A.R. et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289, 1-16 (2004).
48. Bourdage, J.S., Cook, C.A., Farrington, D.L., Chain, J.S. & Konrad, R.J. An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug. J. Immunol. Methods 327, 10-17 (2007).
49. Hanke, T. Lessons from TGN1412. Lancet 368, 1569-1570; author reply 1570 (2006).
50. Waibler, Z. et al. Toward experimental assessment of receptor occupancy: TGN1412 revisited. J. Allergy Clin. Immunol. 122, 890-892 (2008).